References
- Koller KM, Mackley HB, Liu J, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther 2017;18:36-42. https://doi.org/10.1080/15384047.2016.1264543
- Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014;3:e28780. https://doi.org/10.4161/onci.28780
- Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011;47:2150-7. https://doi.org/10.1016/j.ejca.2011.06.052
- Beaver JA, Theoret MR, Mushti S, et al. FDA approval of nivolumab for the first-line treatment of patients with BRAF(V600) wild-type unresectable or metastatic melanoma. Clin Cancer Res 2017;23:3479-83. https://doi.org/10.1158/1078-0432.CCR-16-0714
- Barone A, Hazarika M, Theoret MR, et al. FDA Approval Summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma. Clin Cancer Res 2017;23:5661-5. https://doi.org/10.1158/1078-0432.CCR-16-0664
- Chuk MK, Chang JT, Theoret MR, et al. FDA Approval Summary: accelerated approval of pembrolizumab for secondline treatment of Metastatic Melanoma. Clin Cancer Res 2017;23:5666-70. https://doi.org/10.1158/1078-0432.CCR-16-0663
- Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci 2014;15:927-43. https://doi.org/10.3390/ijms15010927
- Kumari A, Simon SS, Moody TD, Garnett-Benson C. Immunomodulatory effects of radiation: what is next for cancer therapy? Future Oncol 2016;12:239-56. https://doi.org/10.2217/fon.15.300
- Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol 1953;26:234-41. https://doi.org/10.1259/0007-1285-26-305-234
- Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett 2015;356:82-90. https://doi.org/10.1016/j.canlet.2013.09.018
- Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev 2017;280:249-79. https://doi.org/10.1111/imr.12573
- Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer 2016;40:25-37. https://doi.org/10.1016/j.currproblcancer.2015.10.001
- Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015;4:e1046028. https://doi.org/10.1080/2162402X.2015.1046028
- Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 2018;18:313-22. https://doi.org/10.1038/nrc.2018.6
- Chicas-Sett R, Morales-Orue I, Rodriguez-Abreu D, Lara-Jimenez P. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: a systematic review. Clin Transl Radiat Oncol 2017;9:5-11. https://doi.org/10.1016/j.ctro.2017.12.004
- Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 2015;16:795-803. https://doi.org/10.1016/S1470-2045(15)00054-6
- Hiniker SM, Reddy SA, Maecker HT, et al. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int J Radiat Oncol Biol Phys 2016;96:578-88. https://doi.org/10.1016/j.ijrobp.2016.07.005
- Muldoon LL, Alvarez JI, Begley DJ, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab 2013;33:13-21. https://doi.org/10.1038/jcbfm.2012.153
- Negi N, Das BK. CNS: Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ. Int Rev Immunol 2018;37:57-68. https://doi.org/10.1080/08830185.2017.1357719
- Franchino F, Ruda R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain. Front Oncol 2018;8:161. https://doi.org/10.3389/fonc.2018.00161
- Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884-98. https://doi.org/10.1634/theoncologist.12-7-884
- Ishiyama H, Teh BS, Ren H, et al. Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier? Clin Genitourin Cancer 2012;10:196-8. https://doi.org/10.1016/j.clgc.2012.01.004
- Okwan-Duodu D, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol 2015;38:119-25. https://doi.org/10.1097/COC.0b013e3182940dc3
- Long GV, Eroglu Z, Infante J, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol 2018;36:667-73.
- Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAFmutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444-51. https://doi.org/10.1016/S0140-6736(15)60898-4
- Moriceau G, Hugo W, Hong A, et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 2015;27:240-56. https://doi.org/10.1016/j.ccell.2014.11.018
- Long GV, Fung C, Menzies AM, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun 2014;5:5694. https://doi.org/10.1038/ncomms6694
- Wagle N, Van Allen EM, Treacy DJ, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014;4:61-8. https://doi.org/10.1158/2159-8290.CD-13-0631
- Johnson DB, Menzies AM, Zimmer L, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer 2015;51:2792-9. https://doi.org/10.1016/j.ejca.2015.08.022
- Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017;28:1631-9. https://doi.org/10.1093/annonc/mdx176
- Lim SY, Menzies AM, Rizos H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer 2017;123(S11):2118-29. https://doi.org/10.1002/cncr.30435
- Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016;17:1248-60. https://doi.org/10.1016/S1470-2045(16)30122-X
- Rausch MP, Hastings KT. Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application. In: Ward WH, Farma JM, editors. Cutaneous melanoma: etiology and therapy. Brisbane, Australia: Codon Publications; 2017.
- Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 2015;5:202. https://doi.org/10.3389/fonc.2015.00202
- Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84. https://doi.org/10.1016/S1470-2045(15)70076-8
- Hazarika M, Chuk MK, Theoret MR, et al. U.S. FDA Approval Summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res 2017;23:3484-8. https://doi.org/10.1158/1078-0432.CCR-16-0712
- Ko EC, Formenti SC. Radiotherapy and checkpoint inhibitors: a winning new combination? Ther Adv Med Oncol 2018 Apr 11 [Epub]. http://doi.org/10.1177/1758835918768240.
Cited by
- Systemic Antitumor Effects and Abscopal Responses in Melanoma Patients Receiving Radiation Therapy vol.98, pp.4, 2019, https://doi.org/10.1159/000505487
- Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases vol.10, pp.4, 2019, https://doi.org/10.1002/cam4.3716
- Chimeric antigen receptor T-cell therapy for melanoma vol.17, pp.3, 2019, https://doi.org/10.1080/1744666x.2021.1880895
- Bystander effect and abscopal effect in recurrent thymic carcinoma treated with carbon-ion radiation therapy: A case report vol.9, pp.22, 2019, https://doi.org/10.12998/wjcc.v9.i22.6538
- Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes? vol.10, pp.21, 2019, https://doi.org/10.3390/jcm10215124
- A case of primary malignant melanoma of the esophagogastric junction with abscopal effect after nivolumab administration vol.7, pp.1, 2021, https://doi.org/10.1186/s40792-021-01336-y